Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
about
Structure prediction and validation of the ERK8 kinase domainRecent advances of novel targeted therapy in non-small cell lung cancerAcquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainEGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly headTen things you should know about protein kinases: IUPHAR Review 14A systematic interaction map of validated kinase inhibitors with Ser/Thr kinasesTargeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsStructure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistanceA conserved water-mediated hydrogen bond network defines bosutinib's kinase selectivityAn ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 PseudokinaseFrequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsConservation, variability and the modeling of active protein kinasesMolecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeuticsRe-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpointsQuantitative phosphokinome analysis of the Met pathway activated by the invasin internalin B from Listeria monocytogenes.Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinasesExpression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.A type-II kinase inhibitor capable of inhibiting the T315I "gatekeeper" mutant of Bcr-Abl.A structure-guided approach to creating covalent FGFR inhibitorsActivity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors.Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells.EGFR-T790M is a rare lung cancer susceptibility allele with enhanced kinase activityAurora A and B kinases as targets for cancer: will they be selective for tumors?ErbB receptors and epithelial-cadherin-catenin complex in human carcinomas.The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.Treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.EGFR Inhibition in the Treatment of Non-Small Cell Lung CancerLarge-scale proteomics analysis of the human kinome.An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.Biochemical mechanisms of resistance to small-molecule protein kinase inhibitors.Philadelphia chromosome-positive leukemia stem cells in acute lymphoblastic leukemia and tyrosine kinase inhibitor therapy.The impact of germline mutations on targeted therapy.Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.Advances and challenges in targeting FGFR signalling in cancer.Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.
P2860
Q21090822-A6927150-8641-403E-B33E-22252E4A49F2Q21092930-01DD1C4B-408A-4106-82F8-36E9F2391401Q24794765-64B2F0BE-6EE9-446F-AC46-9FBABE6F1F76Q24794815-B5D054BC-5CE0-401B-B076-A6F106FC645EQ26849417-6FF8552D-F005-4FEE-AB97-C80B7442408DQ27649303-38585BDD-5196-4F6E-8A2B-6CA743C6732CQ27658951-6B71D635-7200-4630-B359-8B96FB2E4D2FQ27678586-91ACF6F2-93E6-4CC0-ADBE-4EF31B249AF7Q27680722-207E68CC-C3E3-4602-9A7A-F7F6FB9CA4B4Q27682355-29184459-A9BA-4FFA-9917-2BD2FA5485D4Q27851615-62C323B1-E13F-4F4F-9BF9-AE52AB6AAA97Q27853244-2D17D64D-342E-4535-9978-85EE45AA39EAQ28469309-BB00DF39-D1A5-45E6-89BD-D7A6DFE285B0Q28544659-3C12CCE5-F8B4-413B-8696-62D83D82EA3FQ30584974-1C3080D3-D76A-42AB-82E2-6B873D91AC41Q33628918-5D621537-307B-4C9D-8C49-4E50F89D8E5EQ33906140-0A781125-8670-4511-94F1-DA1035DAC8A5Q33967180-8FDA6038-6ED7-41AC-B81C-0FD20A4B8759Q34052015-07523908-4F2E-4AA8-A6D5-373E1AC87652Q34061522-76D6B633-959F-457D-A4D6-32F80915D964Q34695008-52465C96-33A9-4F82-B4D6-A3CD20BE1A08Q34992813-9D414C14-F307-4B24-8C3E-BEFBE53C6412Q35944914-E179163E-B1EE-45A9-BB0B-3E1671A03C7DQ36140620-18D6264C-B561-4A55-A78F-7176214EB961Q36285611-8FE1D348-F3E1-480F-B1DF-4431EA977248Q36352091-5665FB8F-D54C-4806-8C63-D8252E7EFEE5Q36677496-6B592154-853B-43DD-82D7-AE5D9E81A5A1Q37061044-E8A6857A-1D2B-4DEB-8979-F6AEBEB15FD0Q37152745-1CF366CF-DBF5-4154-B4FE-771FBCB3054EQ37240726-2DC32021-EF35-411E-BD31-7D34989BEC6DQ37258113-32DE817D-13D7-4738-BCB6-8295A55A3DB4Q37334825-BF483851-4253-41CC-8950-BE30F9C992FEQ37665845-C93D3E06-BEEF-4731-A29B-50575BB5F1A1Q38044901-E6D05ADF-CFCE-4D25-82DE-44A8EE315E6FQ38151546-E902A030-B2A3-4C43-B29A-EF12AC7E3BB2Q38255064-F2BC8515-2514-44CB-85CE-F5D9F2A161B2Q39183442-52663F86-64FD-4ACE-A712-5585F6F16F1DQ39186300-07411ECC-8479-40A3-B397-4D5E4C885984Q40286391-660665D7-18CB-47B5-892F-DAEEE88EFD3AQ40505693-9D8F6B56-EDA6-4733-8CF5-633CBD6D265A
P2860
Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Characterization of a conserve ...... ivity to selective inhibitors.
@en
Characterization of a conserve ...... ivity to selective inhibitors.
@nl
type
label
Characterization of a conserve ...... ivity to selective inhibitors.
@en
Characterization of a conserve ...... ivity to selective inhibitors.
@nl
prefLabel
Characterization of a conserve ...... ivity to selective inhibitors.
@en
Characterization of a conserve ...... ivity to selective inhibitors.
@nl
P2093
P1476
Characterization of a conserve ...... tivity to selective inhibitors
@en
P2093
Axel Ullrich
Birgit Zech
György Kéri
Henrik Daub
Stephanie Blencke
Zoltán Greff
Zoltán Horváth
P304
P356
10.1016/J.CHEMBIOL.2004.02.029
P577
2004-05-01T00:00:00Z